Indefinite Delivery Contract 75N95022D00005
Award Date
2/15/22
Last Date to Order
2/14/27
Federal Agency
National Institute on Drug Abuse
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Walsh Healy Act
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The Department of Health and Human Services' National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) has awarded a single-award indefinite delivery contract to Polypeptide Laboratories San Diego, LLC, a Contract Development & Manufacturing Organization (CDMO), to provide chemistry, manufacturing, and controls (CMC) services for the development of drug substances. This five-year, $49.7 million IDV contract, awarded without set-asides, supports NCATS'...
The National Institute on Drug Abuse (NIDA), a civilian agency under the Department of Health and Human Services, has awarded an Indefinite Delivery Contract to Research Triangle Institute (RTI International), a non-profit research organization, to provide synthesis and distribution services for drugs of abuse and related compounds. The contract has a ceiling value of $14,004,330 and a period of performance from June 9, 2022 to June 8, 2027. This contract supports NIDA's mission of conducting...
The National Institute on Drug Abuse (NIDA), a civilian agency within the U.S. Department of Health and Human Services, awarded a $7 million indefinite delivery contract to Murty Pharmaceuticals, Inc., a small disadvantaged minority-owned business, for the development and manufacture of pharmaceutical products to support NIDA's substance abuse and addiction treatment research programs. Under this contract, Murty Pharmaceuticals performs a range of services including formulation development,...
The National Institute on Drug Abuse (NIDA), a civilian agency, has awarded an Indefinite Delivery Contract (IDC) valued at up to $10,000,000 to Benuvia Operations, LLC, a for-profit organization. The 5-year IDC, awarded on March 14, 2025, will provide GMP synthesis of bulk drug substances, including the synthesis of GMP psilocybin, for NIDA's toxicological and clinical trials program. The contract requires the vendor to have the capability to manufacture both GMP and non-GMP bulk drug...
The National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), has awarded an Indefinite Delivery Contract (IDC) to Actuated Medical, Inc., doing business as Piezo Resonance Innovations Inc. The $35 million, single-award IDC runs through September 2028 and is for research and development services related to biocompatibility testing, animal studies, and sterilization testing in support of NIDA's Blueprint MedTech (BPMT) Initiative. This work involves...
The National Institutes of Health (NIH) National Institute on Drug Abuse (NIDA) awarded a $6.5 million single-award Indefinite Delivery Contract (IDC) to the Lovelace Biomedical Research Institute, a not-for-profit contract research organization, to assess potential treatments for drug-induced respiratory depression and overdose toxicity. The contract has a period of performance from September 26, 2022 to September 25, 2027. Under this IDC, NIDA has issued several cost-plus-fixed-fee delivery...
The National Institute on Drug Abuse (NIDA), a civilian federal agency, awarded a single-award Indefinite Delivery Contract to Research Triangle Institute (RTI International), a non-profit research organization, for the preparation and distribution of research drug products. The $19,975,000 contract has a period of performance from March 20, 2025 to March 19, 2029, with a final completion date of March 19, 2026 for the initial $1,497,865 delivery order. RTI International, an experienced...
This $49.9 million Indefinite Delivery Contract was awarded by the National Institute on Drug Abuse (NIDA), a civilian agency, to PPD Development LP, a global contract research organization (CRO) subsidiary of Thermo Fisher Scientific. The contract is for research and development related to clinical studies under NIDA's Blueprint MedTech program, which focuses on medical technology development for nervous system disorders. Under this IDC, PPD will provide a range of services including developing...
The National Institute on Drug Abuse (NIDA) has awarded an Indefinite Delivery Contract (IDC) to Infinity Biologix LLC, doing business as Sampled Division, to maintain and expand the NIDA Center for Genetic Studies (NCGS) over a 5-year period. The $15,000,000 contract aims to create a repository to receive, process, and store de-identified biospecimens and associated clinical and phenotypic data from NIDA-funded genetic addiction research, and to make these resources widely available to...
The National Institute on Drug Abuse (NIDA), a civilian agency within the U.S. Department of Health and Human Services, awarded an Indefinite Delivery Contract (IDC) with a $49,500,000 ceiling value to The Emmes Company LLC, a for-profit limited liability company, to serve as the Clinical Coordinating Center for NIDA's Clinical Trials Network (CTN). The contract has a period of performance from August 15, 2024 to August 14, 2029. Under this IDC, NIDA has issued three task orders to date,...